1. 1137PDIdentification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444. (23rd October 2018) Authors: Willingham, S; Hotson, A N; Laport, G; Kwei, L; Fong, L; Sznol, M; Powderly, J; Miller, R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 438PSafety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary phase I results from study M15-891. (23rd October 2018) Authors: Powderly, J; Cassier, P A; Cervantes, A; Gao, B; Gazzah, A; Italiano, A; Lin, C-C; Luke, J J; Moreno, V; Peltola, K; Rasco, D; Spira, A I; Tanner, M M E; Tosi, D; Afar, D; Englert, S; Parikh, A; Reddy, A; Vosganian, G; Tolcher, A W Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. (13th September 2018) Authors: Colevas, A D; Bahleda, R; Braiteh, F; Balmanoukian, A; Brana, I; Chau, N G; Sarkar, I; Molinero, L; Grossman, W; Kabbinavar, F; Fassò, M; O'Hear, C; Powderly, J Journal: Annals of oncology Issue: Volume 29:Number 11(2018) Page Start: 2247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗